Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth 
Dollar Weakens Ahead of Expected Federal Reserve Rate Cut 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Oil Prices Hold Steady as Ukraine Tensions and Fed Cut Expectations Support Market 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Novavax raised doubts about the feasibility of continuing its business after struggles in rolling out its coronavirus jab although it has enough money to fund operations.
The COVID-19 vaccine maker, which described the situation as "subject to significant uncertainty," also announced plans to cut spending
On Tuesday, the company reported a loss of $182 million in the fourth quarter, after posting weaker sales than expected at $357 million.
Consequently, Novavax shares plummeted 25 percent in extended trading.
Novavax is currently gearing up for a fall vaccination campaign and said it plans to focus on delivering an updated COVID-19 vaccine.
The Maryland-based Novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays.
The company faced delays in regulatory submissions for its jab, which was only authorized in the US in July last year.
Before that, it received authorization from the European Union, United Kingdom, Canada, and Australia.
